Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | CCR1 | P32246 | 9/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9907220 | 0.82 | GAA (0.50) | GAAHTTALDH1A1USP2LMNA | |
| SCHEMBL9906188 | 0.77 | SMN1; SMN2 (0.46) | GAAALDH1A1LMNACYP2C9 | |
| SCHEMBL9906190 | 0.73 | TSHR (0.47) | ALDH1A1LMNACYP2C9 | |
| SCHEMBL23376913 | 0.72 | MAPT (0.41) | HTTALDH1A1LMNACYP2C9 | |
| SCHEMBL9906161 | 0.72 | MAPT (0.41) | HTTALDH1A1LMNACYP2C9 | |
| SCHEMBL9906160 | 0.72 | MAPT (0.41) | HTTALDH1A1LMNACYP2C9 | |
| SCHEMBL9906156 | 0.72 | MAPT (0.41) | HTTALDH1A1LMNACYP2C9 | |
| SCHEMBL24858699 | 0.71 | ALDH1A1 (0.43) | HTTALDH1A1LMNACYP2C9 | |
| SCHEMBL28731719 | 0.71 | ALDH1A1 (0.47) | GAAHTTALDH1A1LMNACYP2C9 | |
| SCHEMBL9906184 | 0.71 | ALDH1A1 (0.53) | GAAHTTALDH1A1USP2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8198445-B2 | Phosphoramide compound, method for producing the same, ligand, complex, catalyst and method for producing optically active alcohol | NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY (JP) | 2012-06-12 | — | — | US | disclosed |
| US-20100113786-A1 | PHOSPHORAMIDE COMPOUND, METHOD FOR PRODUCING THE SAME, LIGAND, COMPLEX, CATALYST AND METHOD FOR PRODUCING OPTICALLY ACTIVE ALCOHOL | NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY (JP) | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113786-A1 | PHOSPHORAMIDE COMPOUND, METHOD FOR PRODUCING THE SAME, LIGAND, COMPLEX, CATALYST AND METHOD FOR PRODUCING OPTICALLY ACTIVE ALCOHOL | ADH1C, ADH1A, DERA | DPP4 3835/4885GAA 2907/4885HTT 4744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.